Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

A TCR bispecific pipeline starts to build behind Immunocore’s Kimmtrak

At least nine TCR bispecifics are in Phase I or preclinical development for solid tumors

February 2, 2022 6:38 PM UTC

FDA’s approval last week of Immunocore’s Kimmtrak marked a turning point for bispecifics in solid tumors and a first for any TCR bispecific. The success is likely to trigger investment in new TCR bispecific platforms, but for now the modality’s pipeline is limited in target breath and biotech players. 

Unlike traditional bispecific antibodies that combine antibody domains against two distinct cell surface antigens, TCR bispecifics combine a standard antibody domain with one that functions as a T cell receptor. The TCR piece of the bispecific enables it to target peptides that are derived from intracellular targets and bound to MHC molecules on the cell surface. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article